Chapter 7: Radioactive Iodine Treatment in Differentiated Thyroid Cancer

Abstract

Radioactive iodine (RAI) has been used in the treatment of differentiated thyroid cancer (DTC) since many decades. However, there is growing evidence to suggest that RAI may be avoided in low-risk group and is recommended in intermediate and high risk categories of DTC. This article incorporates literature review followed by a consensus of experts to conclude the role of RAI in DTC. The goals of RAI treatment, patient preparation, selection, and doses of RAI treatment in various risk categories are discussed. The follow-up after RAI treatment, side effects, and contraindications to RAI treatment are explained.